Low serum creatinine and risk of diabetes: The Japan Epidemiology Collaboration on Occupational Health Study

Huanhuan Hu1*, Tohru Nakagawa2, Toru Honda2, Shuichiro Yamamoto2, Hiroko Okazaki3, Makoto Yamamoto4, Toshiaki Miyamoto5, Masafumi Eguchi6, Takeshi Kochi6, Makiko Shimizu7, Taizo Murakami7, Kentaro Tomita8, Takayuki Ogasawara9, Naoko Sasaki9, Akiko Uehara10, Isamu Kabé6, Tetsuya Mizoue1, Tomofumi Sone12, Seitaro Dohi3, for the Japan Epidemiology Collaboration on Occupational Health Study Group

1Department of Epidemiology and Prevention, National Center for Global Health and Medicine, Tokyo, 2Hitachi, Ltd., Ibaraki, 3Mitsui Chemicals, Inc., Tokyo, 4Yamaha Corporation, Shizuoka, 5Nippon Steel and Sumitomo Metal Corporation Kimitsu Works, Chiba, 6Furukawa Electric Co., Ltd., Tokyo, 7Mizue Medical Clinic, Keihin Occupational Health Center, Kanagawa, 8Mitsubishi Plastics, Inc., Tokyo, 9Mitsubishi Fuso Truck and Bus Corporation, Kanagawa, 10Sejin Kai Shuzui Hospital, Hokkaido, 11Teikyo University Graduate School of Public Health, Tokyo, and 12National Institute of Public Health, Saitama, Japan

Keywords
Diabetes, Serum creatinine, Skeletal muscle

*Correspondence
Huanhuan Hu
Tel.: +81-3-3202-7181
Fax: +81-3-3202-7364
E-mail address:
hu.huanhuan@yahoo.com

J Diabetes Investig 2019; 10: 1209–1214
doi: 10.1111/jdi.13024

INTRODUCTION
Skeletal muscle is a primary target for insulin action1. Thus, decreased skeletal muscle mass could potentially trigger insulin resistance2,3, which is an underlying mechanism of diabetes. Two cohort studies from Korea have shown that low muscle mass, defined using relative muscle mass and muscle mass index (appendicular), respectively, is linked with a greater risk of incident diabetes in both young and old people4,5.

Creatinine is the only metabolite of creatine phosphate in the skeletal muscle. Under the steady state, it is created at a relatively constant rate by the body depending on the total skeletal muscle mass6. Because of the close association between muscle mass and creatinine (correlation coefficient ≥0.7)7,8, serum creatinine is also used as an inexpensive, easily available surrogate of muscle mass when the kidney functions are stable and protein intake is normal. Thus, it would be interesting to examine a potential association between low serum creatine and the development of diabetes. Three cohort studies from Japan and one from China reported that low serum creatinine was
associated with an elevated risk (hazard ratios [HRs] ranging from 1.4 to 2.0) of diabetes\(^9,12\). However, these cohort studies had some limitations, including short mean follow-up periods (≤4 years)\(^9,12\), lack of adjustment for potentially important diabetes risk factors (for example, smoking and dyslipidemia)\(^10,11\) or the use of fasting glucose only for diagnosing diabetes\(^9,11\). Furthermore, all of these studies assessed serum creatinine at baseline only. In addition, no study has examined the creatinine–diabetes association among those with prediabetes, which represents a high risk for diabetes.

Thus, we investigated a prospective association between serum creatinine levels and diabetes risk using repeated measures of creatinine in a male working population in Japan.

**METHODS**

**Study design**

We analyzed data from the Japan Epidemiology Collaboration on Occupational Health Study, which is an ongoing cohort study among workers of 12 companies in Japan (study description in the Appendix S1)\(^13,14\). Briefly, the workers in the participating companies underwent a health checkup every year. They also completed a questionnaire about their medical history and lifestyle. The study protocol, including the consent procedure, was approved by the ethics committee of the National Center for Global Health and Medicine, Japan. In the present study, the 2008 health checkup was considered as the baseline. Two companies had large amounts of missing data in 2008, thus the dataset of 2009 and 2010, respectively, for each company was used as the baseline. We determined the outcome of the present prospective analysis using data of a maximum 8-year follow-up from the baseline through March 2017.

**Study participants**

The present study included only male workers, because the number of women was small (only approximately 100 women or with missing data on blood glucose (417) or cancer (n = 193), cardiovascular disease (n = 417) or cancer (n = 239) at baseline to eliminate the influence, if any, of these diseases on serum creatinine. Workers with serum creatinine >1.2 mg/dL, suggestive of renal dysfunction, were also excluded (n = 193)\(^15\). After further excluding those with missing data on smoking, body mass index (BMI), dyslipidemia and hypertension (n = 388), 32,917 participants remained. We further excluded those who did not attend any subsequent health checkups (n = 1,245) or who attended, but did not receive, glucose measurement (n = 329). Finally, 31,343 participants remained in the analysis.

**Outcome**

We assessed the levels of serum creatinine using the enzymatic method. To minimize misclassification of exposure, we calculated the cumulative average of serum creatinine from baseline examination up to the start of each follow-up interval. For example, the incidence of diabetes between 2009 and 2010 was related to the average serum creatinine measured at the 2008 and 2009 health checkups, and the incidence of diabetes between 2010 and 2011 was related to the average serum creatinine measured at the 2008, 2009 and 2010 health checkups. The cumulative average of serum creatinine was divided into four categories (<0.7, 0.7–0.79, 0.8–0.89 and 0.9–1.2 mg/dL) according to serum creatinine distribution among participants and with reference to the cut-off points used in previous studies\(^9,11\).

**Covariates**

Covariates included baseline age, worksite, smoking, BMI, hypertension and dyslipidemia. We refer to Appendix S1 for the data collection methods, which have been described in previous studies\(^13,14\).

**Statistical analysis**

Basic characteristics of the present study participants were determined as means (standard deviations) and percentages for continuous and categorical variables, respectively. We tested trend association by carrying out a linear regression analysis for continuous variables and the Cochran–Armitage trend test for categorical variables.

Person-time for each participant was counted by subtracting the date of the baseline survey from the date when incident diabetes was first identified or the date of last health checkup, whichever happened first. We used Cox proportional hazards regression analysis to calculate the HR and 95% confidence interval (CI) for risks of incident diabetes related to cumulative average serum creatinine, which was treated as a time-varying variable. In model 1, we adjusted for worksite and age. Furthermore, we adjusted for BMI, dyslipidemia, smoking and hypertension in model 2. Additionally, we examined the creatinine–diabetes association among the participants with prediabetes at baseline, defined as HbA1c 5.7–6.4% and/or fasting glucose 100–125 mg/dL\(^16\).

Stratified analysis was carried out by the baseline age (<45 or ≥45 years), BMI (<21, 21–24.9 and ≥25 kg/m\(^2\)), smoking (yes/no), dyslipidemia status (yes/no) and hypertension status (yes/no), which are associated with both diabetes risk and serum
creatinine levels. All of the statistical analyses were carried out using SAS version 9.3 (SAS Institute, Cary, NC, USA). Statistical significance was established as two-sided \( P < 0.05 \).

**RESULTS**

Table 1 presents participants' characteristics according to the baseline serum creatinine categories. Those with lower serum creatinine were older, tended to be current smokers, and had higher mean high-density lipoprotein cholesterol, blood pressure and fasting glucose.

With a median observation of 7.7 years (range 0.2–9.1 years), 2,509 of the participants developed diabetes. The crude incidence rate was 12.3 per 1,000 person-years. As presented in Table 2, worksite- and age-adjusted HR for diabetes among the participants with serum creatinine <0.70 mg/dL was 1.36 (95% CI 1.18–1.58) compared with people with serum creatinine 0.9–1.2 mg/dL (\( P \) for trend <0.001). After further adjusting for dyslipidemia, BMI, smoking and hypertension, the association was strengthened (HR 1.56, 95% CI 1.35–1.82). Among the participants with prediabetes at baseline, the multivariable-adjusted HR was 1.45 (95% CI 1.23–1.70) for those with creatinine <0.70 mg/dL compared with serum creatinine 0.90–1.20 mg/dL (\( P \) for trend <0.001).

Table 3 presents the association of the cumulative average serum creatinine with diabetes in the stratified analysis. The creatinine–diabetes association was more pronounced among older adults compared with younger adults (\( P \) for interaction by age group = 0.001). The serum creatinine–diabetes association did not differ by BMI levels, smoking status, hypertension status or dyslipidemia status (all \( P \) for interactions >0.05).

**DISCUSSION**

Using repeated measurements of serum creatinine, we found that lower levels of cumulative average serum creatinine were associated with an increased risk of diabetes. Similar findings were observed among the participants with prediabetes at baseline. The serum creatinine–diabetes association was more pronounced among the older adults than the younger adults.

The present findings are consistent with those studies using baseline creatinine only. In a 4-year follow-up study of Japanese male workers (\( n = 8,570 \)), the adjusted odds ratio of diabetes was 1.91 for the participants with creatinine 0.40–0.60 mg/dL compared with 0.71–0.80 mg/dL. In another Japanese study of male workers (\( n = 3,313 \), with a median observation of 6.7 years), the adjusted HR was 1.9 for the participants with creatinine 0.38–0.69 mg/dL compared with 0.90–1.10 mg/dL. In a study of a general population in Japan (\( n = 9,667 \), with a mean observation of 5 years), the adjusted HR was 1.40 for men with creatinine ≤0.7 mg/dL compared with 0.9–1.2 mg/dL, and 1.7 for women with serum creatinine ≤0.5 mg/dL compared with 0.7–1.1 mg/dL. A Chinese study of the general population (\( n = 57,587 \), with a mean observation of 3.6 years) also showed that serum creatinine values at baseline were inversely associated with diabetes risk. The present study had a bigger sample (\( n = 31,343 \)) and longer observation period (median follow-up period of 7.7 years) than previous studies. In addition, we used cumulative average serum creatinine over the study period to minimize the misclassification of exposure. Furthermore, we found low concentrations of serum creatinine were associated with the progression from prediabetes to diabetes, extending the serum creatinine–diabetes association to those with prediabetes. With these methodological advantages and extended findings, the present study provides strong evidence that people with lower serum creatinine are at a greater risk of diabetes.

In the stratified analyses, we observed that the serum creatinine–diabetes association did not differ by BMI or smoking status, which is consistent with previous studies.

**Table 1**

| Serum creatinine (mg/dL) | \( n \) | \( \frac{\text{Age (years)}}{\text{BMI (kg/m²)}} \) | \( \text{Current smoker (%)} \) | \( \text{SBP (mmHg)} \) | \( \text{Hypertension (%)} \) | \( \text{FPG (mg/dL)} \) | \( \text{HbA1c (%)} \) | \( \text{TG (mg/dL)} \) | \( \text{HDL-C (mg/dL)} \) | \( \text{LDL-C (mg/dL)} \) | \( \text{Dyslipidemia (%)} \) | \( P \) for trend |
|-------------------------|-------|----------------------------------|----------------------------------|-------------------|-----------------------------|------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| <0.7                    | 1,492 | 44.9 ± 10.4                      | 22.9 ± 3.5                       | 62.1              | 123.1 ± 14.5                | 77.0 ± 10.0      | 55 ± 0.4       | 128.4 ± 127.1  | 58.0 ± 15.5    | 114.6 ± 31.7   | 41.3            | <0.001         |
| 0.7–0.79                | 6,405 | 42.6 ± 10.4                      | 23.0 ± 3.3                       | 52.7              | 121.5 ± 14.2                | 75.8 ± 10.1      | 55 ± 0.4       | 124.3 ± 101.1  | 57.6 ± 14.7    | 117.4 ± 30.8   | 42.5            | <0.001         |
| 0.8–0.89                | 10,848| 42.1 ± 10.2                      | 23.3 ± 3.1                       | 44.5              | 120.6 ± 13.7                | 75.6 ± 9.9       | 55 ± 0.4       | 125.8 ± 95.1   | 56.5 ± 14.0    | 120.0 ± 30.5   | 44.9            | <0.001         |
| 0.9–1.2                 | 12,598| 43.6 ± 9.7                       | 23.7 ± 3.0                       | 34.6              | 120.9 ± 14.0                | 76.5 ± 10.2      | 55 ± 0.4       | 130.0 ± 95.7   | 56.3 ± 14.1    | 123.4 ± 30.3   | 49.0            | <0.001         |

BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting blood glucose; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglycerides.
Furthermore, we found no effect modification by chronic diseases (for example, hypertension or dyslipidemia). With regard to age, we found that the creatinine–diabetes association was significantly stronger in the older participants (aged 45–64 years) than in the younger adults (aged 20–44 years). In contrast, a small cohort study of Japanese male workers (207 cases of incident diabetes) reported no material differences in the association between serum creatinine and diabetes by age. The present findings based on a much larger number of cases of incident diabetes ($n = 2,509$) would not only be statistically

**Table 2** | Associations between cumulative average serum creatinine and incidence of diabetes

| Subgroup | Cases | Person-years | Cumulative average serum creatinine (mg/dL) | $P$ for trend |
|----------|-------|--------------|--------------------------------------------|--------------|
| Overall  |       |              |                                            |              |
|          |       |              | $<$0.7 | 0.7–0.8 | 0.8–0.9 | 0.9–1.2 |
| Cases    | 228   | 636          | 832   | 813     |          |          |
| Person-years | 11,599 | 47,950       | 73,878 | 69,866  |          |          |
| Model 1  | 1.36 (1.18, 1.58) | 1.09 (0.98, 1.21) | 0.98 (0.89, 1.08) | Reference | $<$0.001 |
| Model 2  | 1.56 (1.35, 1.82) | 1.22 (1.09, 1.35) | 1.06 (0.96, 1.17) | Reference | $<$0.001 |
| People with prediabetes at baseline |       |              |                                            |              |
|          |       |              | $<$0.7 | 0.7–0.8 | 0.8–0.9 | 0.9–1.2 |
| Cases    | 198   | 582          | 742   | 745     |          |          |
| Person-years | 5,698 | 21,038       | 30,377 | 29,540  |          |          |
| Model 1  | 1.29 (1.11, 1.52) | 1.09 (0.98, 1.22) | 0.99 (0.89, 1.10) | Reference | $<$0.001 |
| Model 2  | 1.45 (1.23, 1.70) | 1.19 (1.06, 1.33) | 1.05 (0.95, 1.16) | Reference | $<$0.001 |
| People with normoglycemia at baseline |       |              |                                            |              |
|          |       |              | $<$0.7 | 0.7–0.8 | 0.8–0.9 | 0.9–1.2 |
| Cases    | 30    | 54           | 90    | 68      |          |          |
| Person-years | 5,900 | 26,911       | 43,501 | 40,325  |          |          |
| Model 1  | 2.54 (1.64, 3.95) | 1.11 (0.77, 1.60) | 1.18 (0.86, 1.62) | Reference | 0.005    |
| Model 2  | 2.48 (1.59, 3.89) | 1.18 (0.82, 1.68) | 1.22 (0.89, 1.68) | Reference | 0.003    |

Model 1: adjusted for age and worksite. Model 2: adjusted for age, worksite, smoking, body mass index, hypertension and dyslipidemia.

**Table 3** | Associations between cumulative average serum creatinine and diabetes in subgroups

| Subgroup | Cases | Person-years | Cumulative average serum creatinine (mg/dL) | $P$ for trend |
|----------|-------|--------------|--------------------------------------------|--------------|
| Overall  |       |              |                                            |              |
|          |       |              | $<$0.7 | 0.7–0.8 | 0.8–0.9 | 0.9–1.2 |
| Age (years)$^\dagger$ |       |              |                                            |              |
| <45      | 902   | 122,370      | 1.32 (1.02, 1.71) | 0.95 (0.79, 1.14) | 0.91 (0.77, 1.06) | Reference | $<$0.001 |
| $\geq$45 | 1,607 | 80,920       | 1.66 (1.37, 2.00) | 1.37 (1.20, 1.57) | 1.15 (1.01, 1.30) | Reference | $<$0.001 |
| BM (kg/m$^2$)$^\ddagger$ |       |              |                                            |              |
| <21.0     | 233   | 45,210       | 1.51 (0.94, 2.41) | 1.33 (0.91, 1.93) | 1.09 (0.75, 1.57) | Reference | 0.044    |
| 21.0–24.9 | 1,054 | 106,383      | 1.42 (1.12, 1.80) | 1.21 (1.03, 1.43) | 1.06 (0.91, 1.23) | Reference | $<$0.001 |
| $\geq$25.0 | 1,222 | 51,697       | 1.64 (1.32, 2.05) | 1.19 (1.02, 1.37) | 1.05 (0.91, 1.20) | Reference | $<$0.001 |
| Smoking$^\S$ |       |              |                                            |              |
| Current   | 1,212 | 87,770       | 1.57 (1.29, 1.91) | 1.24 (1.06, 1.45) | 0.98 (0.85, 1.15) | Reference | $<$0.001 |
| Never/former | 1,297 | 115,521      | 1.47 (1.15, 1.87) | 1.17 (1.01, 1.36) | 1.11 (0.98, 1.27) | Reference | $<$0.001 |
| Hypertension$^§$ |       |              |                                            |              |
| Yes       | 750   | 29,299       | 1.24 (0.93, 1.66) | 1.35 (1.12, 1.64) | 1.02 (0.85, 1.22) | Reference | 0.01     |
| No        | 1,759 | 173,992      | 1.70 (1.42, 2.03) | 1.18 (1.03, 1.34) | 1.07 (0.96, 1.21) | Reference | $<$0.001 |
| Dyslipidemia$^§$ |       |              |                                            |              |
| Yes       | 1,634 | 91,162       | 1.43 (1.18, 1.74) | 1.21 (1.06, 1.38) | 1.04 (0.92, 1.17) | Reference | $<$0.001 |
| No        | 875   | 112,189      | 1.72 (1.36, 2.18) | 1.22 (1.02, 1.47) | 1.09 (0.91, 1.29) | Reference | $<$0.001 |

$^\dagger$Adjusted for age, worksite, smoking, body mass index, hypertension, and dyslipidemia. $^\ddagger$Adjusted for age, worksite, body mass index, hypertension and dyslipidemia. $^\S$Adjusted for age, worksite, smoking, body mass index and dyslipidemia (or hypertension).

Furthermore, we found no effect modification by chronic diseases (for example, hypertension or dyslipidemia). With regard to age, we found that the creatinine–diabetes association was significantly stronger in the older participants (aged 45–64 years) than in the younger adults (aged 20–44 years). In contrast, a small cohort study of Japanese male workers (207 cases of incident diabetes) reported no material differences in the association between serum creatinine and diabetes by age. The present findings based on a much larger number of cases of incident diabetes ($n = 2,509$) would not only be statistically...
reliable, but also reasonable from a mechanistic viewpoint. As creatinine is created proportionally to total skeletal muscle mass, low creatinine levels could be an indication of age-associated loss of muscle mass. This aging-related muscle loss has been proposed to increase diabetes risk through several pathways: (i) skeletal muscle tissue is a major target of insulin action, therefore, muscle loss with age results in a diminished target of insulin, and worsens insulin sensitivity and glucose regulation; (ii) aging-related declines in muscle quality can lead to oxidation and inflammation, which cause insulin resistance by inhibiting insulin signal transduction; and (iii) fatty infiltration in skeletal muscle that occurs with aging can lead to insulin resistance. Given that aging is also associated with the impairment of β-cell function, it is assumed that older adults are more likely to develop diabetes than younger adults in the presence of insulin resistance. If this is the case, older people might benefit more than younger people from strength training, which increases muscle and consequently improves insulin sensitivity. In fact, a study in Japan reported a greater reduction in diabetes risk related to strength training in people aged ≥50 years than their younger counterparts. More studies are required to confirm these findings.

The present study had several strengths, including the large cohort, long-term observation, use of blood glucose and HbA1c for diagnosing diabetes, sufficient cases of diabetes, and annual assessment of serum creatinine. Some limitations also warrant attention. First, serum creatinine was measured in different laboratories in the Japan Epidemiology Collaboration on Occupational Health study. Given that all the laboratories in the present study received high-quality control scores from external agencies, we believe that the measurement is reliable and comparable across participating companies. To further confirm this, we repeated the analysis with data from a big company and found that the adjusted HR was 1.52 (95% CI 1.27–1.81) for men with creatinine <0.70 mg/dL compared with 0.90–1.20 mg/dL, which is similar to the overall analysis. Second, two worksites (approximately 5% of the total study population) did not have disease history data (e.g., kidney disease, hepatitis, cardiovascular disease and cancer) that might have influenced the level of serum creatinine. We confirmed, however, that the results were materially unchanged after excluding people at the two worksites (serum creatinine <0.70 vs 0.90–1.20 mg/dL, adjusted HR 1.56, 95% CI 1.34–1.81). Third, because of the lack of data on potential confounders, such as meat intake, we were unable to control for the potential effects of these factors. Last, the small number of women, especially few (approximately 100) women with serum creatinine <0.50 mg/dL, precluded the assessment of the association between low serum creatinine and diabetes in women.

In conclusion, the present cohort study based on repeated measurements of serum creatinine shows that low serum creatinine is associated with an increased risk of diabetes. Screening serum creatinine levels can be used to identify those at a high risk of diabetes.

ACKNOWLEDGMENTS

This study was supported by the Industrial Health Foundation, Industrial Disease Clinical Research Grants (grant numbers 140202-01, 150903-01, 170301-01), Japan Society for the Promotion of Science KAKENHI (grant number 16H05251), and Grant of National Center for Global Health and Medicine (grant number 28-Shi-1206).

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

1. Zierath JR, Krook A, Wallberg-Henriksson H. Insulin action and insulin resistance in human skeletal muscle. Diabetologia 2000; 43: 821–835.
2. Moon SS. Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009-2010. Endocr J 2014; 61: 61–70.
3. Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PLoS One 2010; 5: e10805.
4. Son JW, Lee SS, Kim SR, et al. Low muscle mass and risk of type 2 diabetes in middle-aged and older adults: findings from the KoGES. Diabetologia 2017; 60: 865–872.
5. Hong S, Chang Y, Jung HS, et al. Relative muscle mass and the risk of incident type 2 diabetes: a cohort study. PLoS One 2017; 12: e0188650.
6. Heymsfield SB, Arteaga C, McManus C, et al. Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr 1983; 37: 478–494.
7. Baxmann AC, Ahmed MS, Marques NC, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 2008; 3: 348–354.
8. Woo KS, Choi JL, Kim BR, et al. Clinical usefulness of serum cystatin C as a marker of renal function. Diabetes Metab J 2014; 38: 278–284.
9. Harita N, Hayashi T, Sato KK, et al. Lower serum creatinine is a new risk factor of type 2 diabetes: the Kansai healthcare study. Diabetes Care 2009; 32: 424–426.
10. Kashima S, Inoue K, Matsumoto M, et al. Low serum creatinine is a type 2 diabetes risk factor in men and women: the Yupot Health Checkup Center cohort study. Diabetes Metab 2017; 43: 460–464.
11. Takeuchi M, Imano H, Muraki I, et al. Serum creatinine levels and risk of incident type 2 diabetes mellitus or dysglycemia in middle-aged Japanese men: a retrospective cohort study. BMJ Open Diabetes Res Care 2018; 6: e000492.
12. Bao X, Gu Y, Zhang Q, et al. Low serum creatinine predicts risk for type 2 diabetes. *Diabetes Metab Res Rev* 2018; 24: e3011.

13. Hu H, Nagahama S, Nanri A, et al. Duration and degree of weight change and risk of incident diabetes: Japan Epidemiology Collaboration on Occupational Health Study. *Prev Med* 2017; 96: 118–123.

14. Hu H, Kurotani K, Sasaki N, et al. Optimal waist circumference cut-off points and ability of different metabolic syndrome criteria for predicting diabetes in Japanese men and women: Japan Epidemiology Collaboration on Occupational Health Study. *BMC Public Health* 2016; 16: 220.

15. Evaluation of elevated creatinine. Available from https://bestpractice.bmj.com/topics/en-us/935 Accessed July 28, 2018.

16. American Diabetes Association Standards of medical care in diabetes—2015. *Diabetes Care* 2015; 38(Suppl 1): 1–94.

17. Bellou V, Belbasis L, Tzoulaki I, et al. Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses. *PLoS One* 2018; 13: e0194127.

18. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function—measured and estimated glomerular filtration rate. *N Engl J Med* 2006; 354: 2473–2483.

19. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. *Clin Chem* 1992; 38: 1933–1953.

20. de Luca C, Olefsky JM. Inflammation and insulin resistance. *FEBS Lett* 2008; 582: 97–105.

21. Hurrel S, Hsu WH. The etiology of oxidative stress in insulin resistance. *Biomed J* 2017; 40: 257–262.

22. Scott D, de Courten B, Ebeling PR. Sarcopenia: a potential cause and consequence of type 2 diabetes in Australia’s ageing population? *Med J Aust* 2016; 205: 329–333.

23. Chang AM, Halter JB. Aging and insulin secretion. *Am J Physiol Endocrinol Metab* 2003; 284: E7–E12.

24. Kuwahara K, Honda T, Nakagawa T, et al. Strength training and risk of type 2 diabetes in a Japanese working population: a cohort study. *J Diabetes Investig* 2015; 6: 655–661.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Appendix S1** | Japan Epidemiology Collaboration on Occupational Health Study design and data collection methods.